Sequoia Financial Advisors LLC Buys 33,451 Shares of Takeda Pharmaceutical Co. $TAK

Key Points

• Sequoia Financial Advisors LLC increased its stake in Takeda Pharmaceutical Co. by 51.8%, acquiring an additional 33,451 shares to reach a total of 98,050 shares valued at $1.516 million.
• Takeda reported $0.52 earnings per share, surpassing estimates, despite revenue of $7.45 billion falling short of expectations; the company maintains a 3.360 EPS guidance for FY 2025.
• Due to recent trading activity, institutional investors currently hold 9.17% of Takeda's shares, with varying positions taken by different firms in the past quarter.

Sequoia Financial Advisors LLC boosted its stake in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 51.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 98,050 shares of the company's stock after purchasing an additional 33,451 shares during the period. Sequoia Financial Advisors LLC's holdings in Takeda Pharmaceutical were worth $1,516,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in TAK. Farther Finance Advisors LLC grew its position in Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after purchasing an additional 1,045 shares during the period. GAMMA Investing LLC grew its position in Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock worth $105,000 after purchasing an additional 1,296 shares during the period. Fifth Third Bancorp grew its position in Takeda Pharmaceutical by 85.5% in the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock worth $78,000 after purchasing an additional 2,411 shares during the period. Sagespring Wealth Partners LLC bought a new stake in Takeda Pharmaceutical in the 1st quarter worth approximately $162,000. Finally, Inscription Capital LLC purchased a new position in shares of Takeda Pharmaceutical in the first quarter worth approximately $303,000. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $13.90 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $15.69. The company has a market capitalization of $44.23 billion, a P/E ratio of 46.33 and a beta of 0.21. The firm's 50 day simple moving average is $14.82 and its two-hundred day simple moving average is $14.76.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The business had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Research analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on TAK. Weiss Ratings reissued a "hold (c+)" rating on shares of Takeda Pharmaceutical in a report on Tuesday. Zacks Research downgraded shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a report on Thursday, August 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold".

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.